Potentially fatal serious cutaneous ARs eg, exfoliative dermatitis, TEN & SJS; observe 1st appearance of skin rash or any other sign of hypersensitivity. Increased risk of serious CV events, principally MI. Use the lowest effective dose for the shortest possible duration in patients w/ CV disease or risk of an adverse CV event; in those taking NSAIDs, especially w/ CV risk factors. May lead to the onset of new HTN or worsening the pre-existing HTN. Patients taking anti-hypertensive w/ NSAIDs may have an impaired anti-hypertensive response. Closely monitor BP during treatment initiation & at regular intervals thereafter. Patients w/ fluid retention or heart failure. Patients w/ risk factors for GI events (eg, elderly, those w/ history of serious GI events, smoking & alcoholism). W/draw immediately when GI bleeding or ulceration occurs. Concurrent use of ASA. Possible cutaneous adverse events (eg, exfoliative dermatitis, TEN & SJS). Renal impairment or history of kidney or liver disease; may exacerbate asthma & HTN. Concomitant use of anticoagulants. Discontinue if diarrhoea or skin rash occurs. Pregnancy; not recommended in late pregnancy due to foetal CV system effects; may cause foetal renal dysfunction leading to oligohydramnios & neonatal renal impairment (in some cases) during use at about 20 wk gestation or later in pregnancy. Not to be taken by nursing mothers. Childn <14 yr.
Sign Out
